Login to Your Account

Jiangsu Hengrui nears finish line with Apatinib for advanced gastric cancer

By Shannon Ellis
Staff Writer

Sunday, June 8, 2014

SHANGHAI – Jiangsu Hengrui Medicine Co. Ltd. released positive phase III data for apatinib at American Society of Clinical Oncology (ASCO) meeting last week and is now waiting for the good word from the CFDA for marketing approval in China. Apatinib, a molecular targeted therapy for the treatment of advanced gastric cancer has been shown to be associated with improved survival in patients with prior failure to second line chemotherapy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription